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Risk of nontyphoidal Salmonella bacteraemia in
African children is modiﬁed by STAT4
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Nontyphoidal Salmonella (NTS) is a major cause of bacteraemia in Africa. The disease
typically affects HIV-infected individuals and young children, causing substantial morbidity
and mortality. Here we present a genome-wide association study (180 cases, 2677 controls)
and replication analysis of NTS bacteraemia in Kenyan and Malawian children. We identify a
locus in STAT4, rs13390936, associated with NTS bacteraemia. rs13390936 is a context-
speciﬁc expression quantitative trait locus for STAT4 RNA expression, and individuals car-
rying the NTS-risk genotype demonstrate decreased interferon-γ (IFNγ) production in sti-
mulated natural killer cells, and decreased circulating IFNγ concentrations during acute NTS
bacteraemia. The NTS-risk allele at rs13390936 is associated with protection against a range
of autoimmune diseases. These data implicate interleukin-12-dependent IFNγ-mediated
immunity as a determinant of invasive NTS disease in African children, and highlight the
shared genetic architecture of infectious and autoimmune disease.
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Nontyphoidal Salmonella (NTS) is a common, and fre-quently fatal, cause of bacteraemia in children and HIV-infected adults in sub-Saharan Africa1. NTS is estimated
to cause 1.9 million episodes of invasive disease resulting in
390,000 deaths annually in Africa2. This burden of disease reﬂects
inadequate control strategies for NTS in sub-Saharan Africa, with
expanding antibiotic resistance3, and no anti-NTS vaccine avail-
able for use in humans4. There is marked inter-individual var-
iation in susceptibility to invasive NTS (iNTS) disease. Both
heritable and acquired risk factors for disease are well docu-
mented, with sickle cell disease5, HIV infection, malnutrition6
and malaria7 all contributing to susceptibility to iNTS disease in
African children.
Genome-wide association studies (GWAS) have been highly
successful in identifying common genetic variants associated with
hundreds of disease traits in diverse populations8, including
infectious diseases in African populations9. We have previously
conducted a GWAS of all-cause bacteraemia in Kenyan children,
in which we were unable to identify genetic determinants of
invasive bacterial disease beyond sickle cell disease, an association
we observed across a broad range of bacterial pathogens,
including NTS10. Despite a smaller sample size, an analysis of
pneumococcal bacteraemia within the same collection, however,
did demonstrate evidence of novel genetic associations at
genome-wide signiﬁcance10, suggesting that in this context the
loss of study power resulting from a substantial reduction in case
numbers is more than offset by the provision of a more precisely
deﬁned phenotype. This observation and the lack of unbiased,
population-based data assessing host genetic susceptibility to
iNTS disease in African populations led us to conduct a GWAS of
NTS bacteraemia in the Kenyan collection10 with additional
replication in a Malawian case–control sample collection.
In this study we report a GWAS of susceptibility to NTS
bacteraemia in African children. We identify a susceptibility locus
for NTS bacteraemia at signal transducer and activator of tran-
scription 4 (STAT4), rs13390936. This NTS-associated genetic
variation is a context-speciﬁc, expression quantitative trait locus
(eQTL) for STAT4 RNA expression in stimulated leucocytes,
where the NTS-associated genotype results in reduced STAT4
RNA expression. We demonstrate that carriage of the NTS-
associated genotype at STAT4 is associated with reduced IFNγ
protein production in stimulated natural killer (NK) cells, and
with reduced serum IFNγ levels in African children with iNTS
infection. Delivery of an effective anti-NTS vaccine is urgently
required. By establishing the importance of IFNγ-mediated
immunity in the control of NTS infection in African children,
our data highlight the need to consider the induction of cell-
mediated immunity in the design and evaluation of such a
vaccine.
Results
NTS GWAS and replication analysis. Following quality control
(QC; Supplementary Tables 1 & 2) and genome-wide imputation,
2847 Kenyan samples (180 cases, 2677 controls) were included in
the GWAS discovery analysis of 5,585,198 (additive model) and
4,669,480 (genotypic model) autosomal single-nucleotide poly-
morphisms (SNPs). Inspection of quantile–quantile plots (Sup-
plementary Fig. 1) and the genomic control inﬂation factors
(λadditive = 1.01, λgenotypic = 1.01) indicate that inclusion of the four
major principal components (Supplementary Fig. 2) as covariates
in the analysis adequately controls for population substructure. In
the discovery analysis, 67 SNPs at 16 loci were suggestively
associated (P< 1 × 10–6) with NTS bacteraemia (Supplementary
Table 3 and Supplementary Fig. 3). SNPs in each of these asso-
ciated loci were selected for genotyping in Kenyan and Malawian
replication samples. Imputation accuracy of SNPs taken forward
for replication genotyping was conﬁrmed in 930 of the Kenyan
discovery samples (33% of the discovery samples; 180 cases, 750
controls) by Sequenom MASSArray (mean r2 = 0.97, Supple-
mentary Table 4).
Following the discovery analysis, an additional 1374 Kenyan
samples (38 cases, 1336 controls) and 489 Malawian samples (150
cases, 339 controls) were included in the replication genotyping
(Supplementary Table 4). In the replication analysis, an intronic
SNP (rs13390936, chr2:191954816) in the STAT4 gene demon-
strated evidence of association with NTS bacteraemia in both the
Kenyan and Malawian replication samples (Fig. 1 and Table 1).
Comparison of the NTS association at rs13390936 under
alternative genetic models demonstrated that the observed
association is best explained by a recessive model (Supplementary
Table 5), with carriage of the minor, TT genotype being
associated with increased risk of NTS bacteraemia. Re-analysis
of the STAT4 locus in the Kenyan discovery samples (181 cases,
2759 controls; this includes samples excluded from the main
analysis for relatedness) using a linear mixed model, to account
for population structure and relatedness, conﬁrms the association
of rs13390936 genotype with NTS bacteraemia (recessive model;
P = 7.14 × 10–7).
Re-imputation of the STAT4 region, with 1000G Phase 3 as a
reference panel, conﬁrmed rs13390936 as the variant most
strongly associated with NTS in both the Kenyan discovery and
replication samples (Fig. 1). A Bayesian analysis of the re-imputed
data demonstrated that a set of seven SNPs, including
rs13390936, has a >95% probability of containing the causal
variant, under the assumption that we have accurately imputed
the single causal SNP in our data (Fig. 1 and Supplementary
Table 6). To more fully conﬁrm imputation accuracy at
rs13390936 in the Kenyan discovery samples, we re-genotyped
rs13390936 in the complete sample collection with high-
resolution melting curve analysis (HRMA). HRMA and imputa-
tion concordance at rs13390396 conﬁrmed imputation accuracy
(r2 = 0.97), and conﬁrmed the association with NTS bacteraemia
(Table 1). In the combined analysis of all samples, under a
recessive model, the association of rs13390936 with NTS
bacteraemia exceeds genome-wide signiﬁcance (ﬁxed-effects
meta-analysis, P= 8.62 × 10–10, odds ratio (OR) 7.61, 95%
conﬁdence interval (CI), 3.98–14.55).
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Fig. 1 Association plot of NTS bacteraemia susceptibility at the STAT4
region in Kenyan children. NTS association at the STAT4 region under the
recessive model in Kenyan discovery samples (n= 180 cases, 2677
controls). rs13390936 is highlighted in blue. SNPs are coloured according
to the strength of linkage disequilibrium (r2) to rs13390936. SNPs in a
credible SNP set, which includes the causal variant with >95% probability,
are ringed with black circles
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Established NTS-risk factors and rs13390936. Malaria, HIV
infection and malnutrition are important, acquired risk factors
for NTS bacteraemia in African children6,7. To address whether
the observed association of rs13390936 with NTS bacteraemia is
independent of these acquired risk factors, we conducted a
Bayesian analysis comparing models of association at rs13390936
with NTS bacteraemia with and without acquired risk factors for
NTS in the Kenyan discovery samples (Supplementary Fig. 4). In
that analysis, the most probable models are those in which
rs13390936 is associated with susceptibility to NTS bacteraemia
with the same effect size in children with and without each of
malaria and malnutrition. The numbers of HIV-infected children
in the Kenyan discovery samples (n = 24, none of which carry the
rs13390936:TT genotype) are too small to permit a stratiﬁed
analysis. To ensure HIV infection did not confound the observed
association between rs13390936 genotype and NTS bacteraemia,
we repeated the association analysis at rs13390936 including only
HIV-uninfected NTS cases (n = 97). In that analysis, the observed
effect size (recessive model; OR 8.49, 95% CI, 2.37–24.28) is in
keeping with that observed in the association analysis including
all samples (Table 1), further supporting the association between
rs13390936 genotype and NTS bacteraemia.
Control samples used in the Kenyan discovery analysis are
taken from a birth cohort, and acquired risk factor data are not
available to perform a regression analysis of NTS bacteraemia risk
adjusted for malaria, malnutrition and HIV. To address this
limitation, we ﬁtted a regression model of rs13390936 association
with NTS bacteraemia in the Malawian replication samples,
including HIV infection, malaria parasitaemia and severe
malnutrition as covariates. In that model, including 396
Malawian children (109 cases, 287 controls) for which complete
covariate data are available, rs13390936 is associated with NTS
bacteraemia under a recessive model (logistic regression, P =
9.96 × 10–3; OR 7.74, 95% CI, 6.18–9.30) independent of HIV,
malaria and malnutrition. This lack of confounding by acquired
risk factors for NTS is in keeping with the absence of observed
association between genetic variation at the STAT4 locus or HIV
and malaria-related phenotypes in GWAS published to date11,12.
To further address the possibility of confounding secondary to
malaria in Kenyan and Malawian children, we used publically
available GWAS summary statistics from the MalariaGEN
consortium GWAS of severe malaria in Gambian, Kenyan and
Malawian children12 (total 5126 cases, 5287 controls; Gambia
2428 cases, 2489 controls; Malawi 1193 cases, 1321 controls;
Kenya 1505 cases, 1477 controls) to assess for any evidence of
association between rs13390936 and severe malaria. In that
dataset, rs13390936 is not associated with severe malaria in
African children (logistic regression; additive model, P = 0.31, OR
0.96, 95% CI, 0.88–1.04; dominant model P = 0.47, OR 0.97, 95%
CI, 0.88–1.06; recessive model P = 0.15, OR 0.76, 95% CI,
0.52–1.11; heterozygous advantage model P = 0.98, OR 0.98,
95% CI, 0.89–1.08).
Rates of HIV and malaria co-infection, but not malnutrition,
among Kenyan and Malawian children with NTS included in the
study are signiﬁcantly different (Supplementary Table 7). The
observed effect size of the rs13390936 association with NTS
bacteraemia is lower in Malawian children than that observed in
Kenyan children, albeit with no evidence of inter-study hetero-
geneity of effect (Table 1). While there is no evidence that the
observed association between rs13390936 genotype and NTS
bacteraemia is the result of confounding secondary to acquired
risk factors for NTS, we further investigated whether there is
evidence that the effect of rs13390936 genotype on NTS disease
risk is modiﬁed by HIV, malaria or malnutrition. We ﬁtted
regression models of NTS bacteraemia and rs13390936 associa-
tion, with and without interaction terms between rs13390936 and
each acquired risk factor, in the same set of Malawian children. In
that analysis, there is no evidence for interaction between carriage
of the rs13390936:TT genotype and HIV status (likelihood ratio
test, P = 0.81), malaria co-infection (likelihood ratio test, P = 0.07)
or malnutrition (likelihood ratio test, P = 0.82) in NTS bacter-
aemia risk.
The sickle cell locus (rs334) has been previously demonstrated
to be associated with increased risk of NTS bacteraemia in
Kenyan children5 (sickle cell disease—HbSS), and with protection
against malaria, and as a consequence, bacteraemia7 (sickle cell
trait—HbAS). In the Kenyan discovery samples (164 cases, 2342
controls), sickle cell disease is associated with increased risk of
NTS bacteraemia (logistic regression, P = 8.30 × 10–5; OR 4.89,
95% CI, 2.10–10.40), and there is no statistically signiﬁcant
evidence (logistic regression, P = 0.65) for an effect of sickle cell
trait (HbAS) on risk of NTS bacteraemia (Supplementary Fig. 5).
As carriage of HbSS is associated with risk of NTS bacteraemia,
and carriage of HbAS is associated with a key risk factor for NTS
bacteraemia (malaria), we sought to assess whether the observed
association at the STAT4 locus is independent of genotype at
rs334. In regression models conditioned on genotype at rs334
(Supplementary Fig. 5), the observed association at rs13390936
with NTS bacteraemia persists when conditioned on HbAS (OR
7.16, 95% CI, 2.68–17.41) and HbSS (OR 8.08, 95% CI,
2.71–21.89).
rs13390936 is associated with STAT4 RNA expression. GWAS-
identiﬁed trait-associated loci are enriched for regulatory DNA
elements13. Given rs13390936 is non-coding, we explored whe-
ther it is associated with gene expression. We analysed the effects
of rs13390936 genotype on STAT4 RNA expression, using eQTL
datasets from previously published and unpublished datasets14–16
of naïve and stimulated primary immune cells from healthy
European adults. To investigate whether this analysis could be
confounded by differential linkage disequilibrium (LD) between
European and African populations, we examined LD patterns at
the NTS-associated locus in individuals of African and European
ancestry included in the study. In that analysis, there is no
Table 1 Association of rs13390936 with NTS bacteraemia in African children
Population Case Control Genotypic model Recessive model
Freq. TT/AT/AA Freq. TT/AT/AA P value P value OR (95% CI)
Kenya (discovery) 0.151 8/40/138 0.107 15/529/2068 1.76 × 10–5 3.33 × 10–6 8.03 (3.34–19.31)
Kenya (replication) 0.146 3/4/30 0.106 12/254/1053 1.83 × 10–3 6.54 × 10–4 9.96 (2.66–37.36)*
Malawi 0.15 6/31/106 0.136 3/86/249 0.039 0.026 4.89 (1.21–19.83)*
Combined 8.62 × 10–10 7.61 (3.98–14.55)
rs13390936 is directly genotyped in all samples by HRMA. Freq. minor allele frequency, OR odds ratio, CI conﬁdence interval, HRMA high-resolution melting curve analysis
*Fisher's exact estimates of effect sizes in the Kenyan (OR= 9.56, P= 6.79 × 10–3) and Malawian (OR= 4.87, P= 0.023) replication samples (without covariates) are comparable to those derived by
logistic regression
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evidence of differential LD at the NTS-associated locus between
the Kenyan discovery GWAS samples and the European samples
used in the eQTL analyses (Supplementary Fig. 6). In naïve
immune cells, rs13390936 genotype was not signiﬁcantly asso-
ciated with STAT4 RNA expression, which was most abundant in
NK cells (Fig. 2a). By contrast, rs13390936 was a signiﬁcant
expression quantitative trait locus (eQTL) for STAT4 RNA
expression in monocytes following stimulation with
lipopolysaccharide for 2 (linear regression, P = 4.52 × 10–5) or 24
h (linear regression, P = 2.65 × 10–5), or IFNγ for 24 h (linear
regression, P = 2.63 × 10–5), with carriers of the NTS-risk geno-
type expressing the least STAT4 in each stimulation condition
(Fig. 2b).
rs13390936 is associated with IFNγ production in NK cells.
There is no established role for STAT4 in monocytes during
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Salmonella infection. By contrast, a major consequence of STAT4
activity is IFNγ production in NK cells and CD4+ T cells. To
better understand the NTS-associated phenotype of rs13390936 at
the protein level in these cells, we recruited 54 healthy European
adults of known genotype at rs13390936 (36 donors carrying the
NTS-protective AA genotype; 18 carrying the NTS-susceptible
TT genotype) via a genotype-selectable bioresource (Oxford
Biobank). In these individuals, we investigated genotype-
dependent IFNγ production in naïve and stimulated NK cells
and CD4+ T cells by intracellular cytokine staining and ﬂow
cytometry. IFNγ production was quantiﬁed at 6 h in naïve cells
and in cells following stimulation with IL-12 and NTS (Fig. 2c).
Donors with the NTS-risk rs13390936 genotype produced a
reduced fraction of IFNγ+ NK cells following stimulation with IL-
12 (linear regression, P = 1.91 × 10–3, meanAA = 1.54%, meanTT =
0.91%) or NTS (linear regression, P = 0.049, meanAA = 17.09%,
meanTT = 10.76%) (Fig. 2d). We observed this genotype-
dependent effect in NK cells but not in CD4+ T cells (Supple-
mentary Fig. 7).
rs13390936 is associated with IFNγ in acute NTS bacteraemia.
To extend our understanding of the IFNγ protein phenotype of
rs13390936 to African children and to determine the effect of
rs13390936 on total IFNγ production during episodes of NTS
bacteraemia, we measured serum IFNγ levels in Malawian chil-
dren admitted to hospital with NTS bacteraemia (n = 106) during
the acute phase of disease and correlated this with genotype at
rs13390936 (Fig. 2e). There is no evidence for association between
genotype at rs13390936 and co-morbidity, clinical features or
outcome in these children (Supplementary Table 8). In keeping
with our results in stimulated NK cells in European adults, serum
IFNγ levels in Malawian children with acute NTS bacteraemia are
dependent on rs13390936 genotype (linear regression, P= 0.016),
independent of age, sex, malnutrition, HIV status and malaria co-
infection. Malawian children carrying the NTS-risk genotype
have reduced circulating IFNγ concentrations (meanAA = 613.9
pg/ml, meanTT = 281.4 pg/ml). Given the importance of CD4+
T cells as a source of IFNγ, to ensure HIV infection did not
confound this association, we also performed this analysis
including only HIV-uninfected children (n = 61). This conﬁrms
the association between serum IFNγ levels during acute NTS
bacteraemia and rs13390936 genotype (linear regression, P=
0.038, Supplementary Fig. 8). In HIV-infected children (n = 43),
there is no evidence for association between serum IFNγ levels
during acute NTS bacteraemia and rs13390936 genotype (linear
regression, P= 0.23, Supplementary Fig. 8). The lack of associa-
tion between rs13390936 genotype and serum IFNγ may simply
reﬂect a lack of power in HIV-infected children, or may reﬂect
other sources of variation in IFNγ response in HIV-infected
children (e.g. CD4+ T cell count).
Bacteraemia risk conferred by rs13390936 is speciﬁc to NTS.
To investigate whether the susceptibility to bacteraemia
associated with rs13390936 is speciﬁc to NTS or results in sus-
ceptibility to other causes of bacteraemia, we conducted a Baye-
sian analysis comparing models of association at rs13390936 with
the major causes of bacteraemia in the Kenyan discovery samples
(Fig. 3a, b). In that analysis, the most probable model is one in
which rs13390936 is associated with susceptibility to NTS bac-
teraemia but not bacteraemia caused by other pathogens. This
suggests that bacteraemia susceptibility conferred by genetic
variation at STAT4 is speciﬁc to NTS in this context.
Again using a Bayesian approach to compare models of
association at rs13390936, we further investigated whether the
increased risk of NTS bacteraemia conferred by rs13390936
genotype is speciﬁc to the two major NTS serovars causing
disease in African children, S. Typhimurium and S. Enteritidis. In
that analysis, in the Kenyan discovery samples, the most probable
model is one in which rs13390936 is associated with susceptibility
to bacteraemia secondary to both S. Typhimurium and S.
Enteritidis (Supplementary Fig. 9). This suggests, in keeping with
these serovars causing clinically indistinguishable syndromes, and
possessing the same acquired risk factors17, that host genetic risk
factors for NTS bacteraemia are shared by both of the major
causative serovars.
rs13390936 is associated with risk of autoimmune disease.
Previously published genetic association studies have implicated
variation at other loci within STAT4 in the pathogenesis of several
autoimmune diseases18–20. To assess the evidence for any shared
genetic aetiology between NTS bacteraemia and autoimmune
disease at rs13390936, we estimated effect sizes and 95% con-
ﬁdence intervals for association at the NTS-associated locus with
eight autoimmune diseases from summary statistics in the
ImmunoBase database21. We observed a protective association
between the NTS-risk allele and a range of autoimmune diseases,
with the strongest evidence of association seen with type 1 dia-
betes, coeliac disease, juvenile idiopathic arthritis, primary biliary
cirrhosis and rheumatoid arthritis (Fig. 3c). The direction of this
effect suggests that, in contrast to its role in NTS-risk, increased
STAT4 expression and IFNγ production enhances the risk of a
range of autoimmune diseases.
Discussion
In this study, we demonstrate that genetic variation in STAT4 is a
determinant of NTS bacteraemia in African children. The NTS-
associated SNP in STAT4 (rs13390936) is intronic, and is asso-
ciated with disease under a recessive model with a large effect size.
In common with many examples of trait-associated genetic var-
iation identiﬁed by GWAS13, rs13390936 acts as, or is in LD with,
a regulatory determinant of STAT4 expression. Regulatory genetic
variation is commonly speciﬁc to cell type and context14, and this
is the case for rs13390936 and STAT4. The role of rs13390936 as
an eQTL for STAT4 RNA in immune cells is only evident fol-
lowing innate immune stimulation. Moreover, the downstream
Fig. 2 RNA and protein phenotypes of rs13390936 genotype. Genotype–phenotype correlations are analysed by regression and analysis of variance. P
values are calculated by F-tests with one degree of freedom. a rs13390936 genotype is not signiﬁcantly associated with STAT4 RNA expression in
unstimulated B cells, monocytes, neutrophils or NK cells. b Healthy European adults carrying the NTS-susceptibility (T) allele have reduced STAT4
expression following LPS (2 and 24 h) and IFNγ (24 h) stimulation in monocytes. c Gating strategy for IFNγ + NK cells. Representative IFNγ expression in
naïve, and IL-12-simulated or NTS-simulated whole blood is shown for healthy European adult donors carrying the NTS-protective AA genotype (blue) and
the NTS-susceptible TT genotype (red). d Healthy European adults with the NTS-susceptible (TT) genotype have signiﬁcantly fewer IFNγ+ NK cells at 6 h
following IL-12 (meanAA= 1.54%, meanTT= 0.91%) or NTS (meanAA= 17.09%, meanTT= 10.76%) stimulation. rs13390936 genotype does not
signiﬁcantly perturb IFNγ+ NK cell numbers in unstimulated whole blood (meanAA= 0.25%, meanTT= 0.19%). e Malawian children (total n= 106, 97 with
complete covariate data included in ﬁnal model; rs13390936: AA, n= 69; TA, n= 24; TT, n= 4) with the NTS-susceptibility (T) allele have reduced
circulating levels of IFNγ during acute NTS bacteraemia (meanAA= 613.9 pg/ml, meanTT= 281.4 pg/ml) in a linear model adjusted for age, sex and NTS-
associated co-morbidity (HIV infection, malnutrition and malaria). Box and whisker plots; boxes depict the upper and lower quartiles of the data, and
whiskers depict the range of the data excluding outliers (outliers are deﬁned as data-points >1.5× the inter-quartile range from the upper or lower quartiles)
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effects of that regulatory variation at the protein level exhibit both
cell type and context speciﬁcity, with rs13390936 genotype
modulating IFNγ production capacity in NK cells, but not CD4+
T cells. We further demonstrate that carriage of the NTS-risk
allele at rs13390936 associates with reduced IFNγ levels in the
serum of African children during acute iNTS disease.
STAT4 is a member of the STAT family of transcription fac-
tors22. In NK cells and CD4+ T cells, STAT4 phosphorylation in
response to IL-12 signalling results in type 1 T helper (TH1)
differentiation and IFNγ production (Fig. 4). The importance of
this pathway in the control of NTS infection in humans has been
established by studies of a group of genetically heterogeneous,
rare primary immunodeﬁciencies, characterized by extreme sus-
ceptibility to poorly pathogenic mycobacteria and NTS, collec-
tively designated Mendelian susceptibility to mycobacterial
disease (MSMD)23–29. While mutations in STAT4 have not been
reported as a cause of MSMD, the described MSMD loci are all in
genes with roles in IL-12-dependent IFNγ production and IFNγ-
mediated immunity (Fig. 4). The role of STAT4 in host immunity
to NTS infection is further supported by the enhanced suscept-
ibility of Stat4-deﬁcient mice to systemic NTS infection30. The
identiﬁcation of regulatory genetic variation affecting IL-12-
dependent IFNγ-mediated immunity as a risk factor for NTS
bacteraemia highlights the common biological determinants of
susceptibility to infectious diseases at the population level and in
individuals with rare primary immunodeﬁciencies.
The identiﬁcation of genetic variation modifying IFNγ pro-
duction in NK cells, but not CD4+ T cells, as a risk factor for NTS
bacteraemia is noteworthy. These observations are in keeping
with ﬁndings in the mouse model of NTS infection, in which NK
cells have been shown to have a protective role in anti-Salmonella
immunity, in an IFNγ-dependent manner31. The observed asso-
ciation between NTS-associated genetic variation, NK cell IFNγ
production and serum IFNγ production in acute NTS bacter-
aemia suggests that NK cells are an important source of IFNγ in
NTS infections in African children. The lack of a similar asso-
ciation between NTS-associated genetic variation and CD4+ T cell
IFNγ production does not preclude an important role for CD4+ T
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cell-derived IFNγ in anti-Salmonella immunity in African chil-
dren. It is, however, consistent with the observation that acqui-
sition of Salmonella-speciﬁc CD4+ T cells in Malawian children
does not result in effective anti-Salmonella immunity32.
A striking feature of MSMD is the narrow and speciﬁc range of
pathogens to which affected individuals are susceptible. In
keeping with this, we demonstrate that bacteraemia susceptibility
conferred by genetic variation at STAT4 is speciﬁc to NTS among
the most frequent causes of bacteraemia in Kenyan children. By
contrast, we observe a protective effect of the NTS-risk allele at
rs13390936 across a range of autoimmune diseases. The obser-
vation that NTS shares a genetic susceptibility locus with a variety
of autoimmune diseases is consistent with previous examples of a
shared genetic architecture between autoimmune and infectious
diseases33, and supports the hypothesis that selection pressure
imposed by infectious agents has impacted the evolution of
autoimmune disease.
A consequence of our use of a birth cohort as the control
population for the Kenyan samples in this study is that we were
unable to correct for transient risk factors (e.g. malaria and
malnutrition) in the discovery analysis. We demonstrate that risk
of NTS bacteraemia conferred by rs13390936 genotype is inde-
pendent of malaria, malnutrition and HIV status in Malawian
children. It is important to recognize, that while our analysis
provides no evidence for acquired NTS-risk factors modifying the
effect of rs13390936 genotype on risk of NTS disease, this study
has limited power to detect such an interaction. It will therefore
be important to establish in future studies, whether the associa-
tion between rs13390936 and risk of NTS bacteraemia is observed
consistently across populations of African children with diverse
rates of HIV, malaria and malnutrition. The limited sample size,
in particular with respect to case numbers, restricted this analysis
to the contribution of common genetic variation (minor allele
frequency >10%) to risk of NTS bacteraemia. Larger sample sizes
will be required to assess the contribution of less common genetic
variants, and variants with smaller effect sizes, on the risk of NTS
bacteraemia in African children.
Taken together, these results identify regulatory genetic varia-
tion in STAT4 as a key determinant of susceptibility to NTS
bacteraemia in African children. We identify IL-12-dependent
IFNγ production in NK cells as a mechanism by which genetic
variation in STAT4 modiﬁes risk of NTS disease. In future studies
it will be important to establish whether NTS-associated genetic
variation also perturbs TH17 responses and IFNγ production in
other cell types. Our data have important implications for the
design of an anti-NTS vaccine for African children, supporting
the development of vaccine candidates that induce robust cell-
mediated immunity to NTS.
Methods
NTS GWAS study cohorts. For the Kenyan study cohort, children (under 13 years
of age) presenting to Kiliﬁ District Hospital, Kenya between 1 August 1998 and 30
October 2010 with all-cause bacteraemia were recruited10. Blood samples for
bacterial culture (BACTEC 9050, Becton Dickinson) were taken from every child
admitted to the hospital during the study period, with the exception of elective
surgical admissions and children admitted following minor accidents. Control
samples were collected as part of a birth cohort study from consecutive births
between 1 May 2006 and 30th April 2008, among the same population as the case
samples in Kiliﬁ district. All control children were recruited under the age of
12 months. Longitudinal follow-up of the control children suggests that the risk of
case–control misclassiﬁcation is negligible (cases of bacteraemia among controls
during follow-up = 12; mortality among controls during follow-up = 49). These case
and control samples were divided into discovery (cases = 1885, controls = 3000)
and replication (cases = 532, controls = 1444) sets for the Wellcome Trust Case
Control Consortium 2 all-cause bacteraemia GWAS10.
From this collection, we extracted children with NTS bloodstream infection (n
= 267) from the bacteraemia cases, and all of the control children (n = 4444) to
perform a genome-wide association analysis of NTS bacteraemia in Kenyan
children. NTS serotyping was performed according to the Kauffman–White
scheme using commercial antisera. As the discovery and replication sample sets
had been genotyped using different platforms (see below), we analysed the
discovery (cases = 218, controls = 3000) and replication sets separately (n = 49,
controls = 1444). Demographics of study cases and controls in both the discovery
and replication sample sets are presented in Supplementary Table 9. The
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frequencies of NTS serotypes and co-morbidities in discovery and replication case
samples is presented in Supplementary Table 7. Following explanation of the study,
written informed consent was obtained from the parent or guardian of each child
included in the study. Ethical approval for study was obtained from the Kenya
Medical Research Institute (KEMRI) National Scientiﬁc Steering and Research
Committees and the Oxford Tropical Research Ethics Committee.
For the Malawian replication study cohort, case samples (n = 150) were
recruited from children following admission to Queen Elizabeth Central Hospital,
Blantyre, Malawi in 2006. Bacterial culture of blood samples was performed using a
BacT/Alert 3D system (bioMérieux) in all children admitted with suspected sepsis.
Identiﬁcation of NTS was performed using API 20E kits (bioMérieux) and NTS
serotyping performed as for the Kenyan isolates. Every child under 16 years of age
admitted with NTS in blood culture was approached for recruitment to the study.
Malawian replication control samples (n = 339) were collected from healthy
children at the Ndirande Health Centre, Blantyre, Malawi between October and
December 2005, and September and November 200634. Unrelated, healthy children
under 16 years of age were eligible for inclusion in the study. Following explanation
of the study, written informed consent was obtained from the parent or guardian of
each child included in the study, and a buccal swab was taken for DNA extraction.
Ethical approval for the study was granted by the College of Medicine Research and
Ethics Committee, College of Medicine, University of Malawi.
NTS discovery GWAS. Genomic DNA was extracted using QIAamp DNA blood
mini kits (Qiagen). Extracted genomic DNA was whole-genome ampliﬁed with
GenomiPhi (GE Healthcare) according to the manufacturer’s instructions. Before
whole-genome genotyping, DNA quality was assessed; DNA concentration was
assayed using PicoGreen (Invitrogen), agarose gel electrophoresis was used to
detect DNA degradation and QC genotypes were assayed using the Sequenom
iPLEX assay35. Genome-wide genotyping of Kenyan discovery cases and controls
was performed with an Affymetrix SNP 6.0 chip. SNP QC ﬁlters were applied as
follows: minor allele frequency (MAF) <1%, info <0.975, Hardy–Weinberg equi-
librium P< 1 × 10–20, plate effect P< 1 × 10–6 and SNP missingness >2%. Fol-
lowing SNP and sample QC (Supplementary Tables 1 & 2) 787,861 autosomal
SNPs from 1536 bacteraemia (including 180 NTS) case and 2677 control indivi-
duals were taken forward for genome-wide imputation with SHAPEIT36 and
IMPUTE237 using all available populations in 1000G Phase1 as a reference panel.
The ﬁrst four principal components of the genome-wide genotyping data
differentiate self-reported ethnicity (Supplementary Fig. 2) and were included in
the NTS association analysis to control for underlying population structure.
Association analysis was performed using the frequentist score test (accounting for
imputed genotype uncertainty) in SNPTEST238 under additive and genotypic
models of association. Following association analysis, genotyped SNPs nominally
associated (P< 1 × 10–3) with NTS were inspected with Evoker and SNPs with
poor cluster separation excluded from further analysis. Further SNP QC exclusions
were applied as follows: model-speciﬁc imputation info score <0.8 and
Hardy–Weinberg equilibrium P< 1 × 10–10. Given the study sample size and
limited power to replicate associations at less common SNPs (Supplementary
Fig. 10), we further excluded SNPs with MAF <10% from the analysis.
NTS GWAS replication. SNPs in 16 genomic regions putatively associated with
NTS bacteraemia (P< 1 × 10–6) in the Kenyan discovery samples were genotyped
in the Kenyan and Malawian replication samples using the Sequenom MASSArray
platform. Inspection of cluster plots (TYPER4.0) revealed good cluster separation
at 25 SNPs, all of which having a call rate in excess of 95%. Samples were excluded
with call rates <80%. Following QC, 416 Malawian samples (135 cases, 281 con-
trols) and 318 Kenyan samples (36 cases, 282 controls) were included in the
replication analysis. The Sequenom MASSArray platform was also used to conﬁrm
imputation accuracy in 930 Kenyan discovery samples (180 cases, 750 controls) at
loci included in the replication analysis (Supplementary Table 4).
The multiplexed Sequenom MASSArray genotyping reaction chosen for
replication did not include the STAT4 region SNP (rs13390936) most signiﬁcantly
associated with NTS in the Kenyan discovery samples. This SNP was therefore
genotyped by HRMA, using the following PCR primers and an unlabelled probe
with a 3′-amino-C7 modiﬁcation: TAGTGAGCCCTAATGTAAATTATGGGAC
(F), CCCTCACCAGTTTCTCCTATATCT (R),
GTGATGTACTTGTTACAAATTTATATTATTACAATA (probe). Ten
microlitres of PCR reactions (1 μl 10x PCR buffer, 1 μl 25 mM MgCl2, 1 μl dNTPs
(2 mM each), 0.05 μl forward primer (10 μM), 0.025 μl reverse primer (100 μM),
0.025 μl unlabelled probe (100 μM), 1 μl LC Green dye, 0.06 μl HotStarTaq DNA
polymerase (Qiagen), 5 μl water and 0.5 μl template DNA (25 ng/μl)) were cycled
(95 °C for 10 min, 55 cycles of 30 s at 95 °C, 56 °C and 72 °C), under mineral oil.
Following the PCR reaction, the DNA was again denatured (95 °C for 1 min) and
cooled to room temperature for 30 min. High-resolution melting was then
performed on a LightScanner (Idaho Technology) at 0.1 °C/s increments between
45 °C and 98 °C. Melt curves were analysed with LightScanner Call-IT 2.0 (Idaho
Technology) using derivative normalized melting plots between 62 °C and 71 °C
(Supplementary Fig. 11). HRMA genotyping of rs13390936 was performed in 1374
Kenyan replication samples (38 cases, 1336 controls) and 489 Malawian samples
(150 cases, 339 controls). HRMA genotyping of rs13390936 was also performed in
all Kenyan discovery samples passing sample QC, including six case samples which
passed sample QC but failed Affymetrix genotyping (186 cases, 2677 controls).
Kenyan replication cases and controls were also genotyped using the
ImmunoChip39. Sample QC ﬁlters (Supplementary Table 1) were applied as for the
discovery samples, resulting in 38 NTS cases and 1336 controls being included in
the analysis. These genotypes were used to generate principal components for the
replication samples, to correct for population stratiﬁcation. A LD-pruned set of
SNPs (n = 27,026) with MAF >1%, call rate >95% (99% if MAF< 5%) and
Hardy–Weinberg equilibrium P< 1 × 10–10 were used to generate principal
components (Supplementary Fig. 12).
Association analysis of Malawian and Kenyan replication samples was
performed in PLINK40. For the Kenyan replication samples, the ﬁrst four principal
components of ImmunoChip genotyping data were included in the model to
account for population structure (Supplementary Fig. 12). We considered a two-
tailed P value <0.05, with the same risk allele in the same model of association as
observed in the Kenyan discovery set, as evidence of replication. For the combined
analysis, a ﬁxed-effects meta-analysis of the three sample collections was performed
in PLINK. To assess evidence for interaction between rs13390936 genotype and
HIV, malaria and malnutrition, logistic regression models of NTS disease
susceptibility, with and without multiplicative interaction terms, were ﬁtted in R. P
values for interactions are calculated with likelihood ratio tests.
Re-imputation and ﬁne-mapping of the STAT4 region. A 1Mb region centred at
rs13390936 was intensively re-imputed in the Kenyan discovery samples without
pre-phasing with IMPUTE2 using 1000G Phase 3 as a reference panel. Imputation
was performed with 1Mb buffer regions and template haplotypes for phasing
increased to 200. This region was also imputed in the Kenyan replication samples
from ImmunoChip genotyping data using the same IMPUTE2 settings. Following
QC as for the Kenyan discovery samples, association analysis of the re-imputed
genotypes was performed using the frequentist score methods in SNPTEST2 under
a recessive model of association. Re-imputed genotypes were further used to test for
association at STAT4, under a recessive model of association, using a linear mixed
model to account for population structure and sample relatedness in GEMMA41.
In this analysis, samples were not excluded according to pairwise relatedness, but
QC thresholds were otherwise as described for the Kenyan discovery samples.
We used a Bayesian approach to identify a set of SNPs with 95% probability of
containing the causal locus at the NTS-associated region42. Approximate Bayes’
factors43 were calculated under a recessive model for each SNP in the NTS-
associated region with a prior distribution of N(0,1). All SNPs were considered
equally likely to be the causal variant a priori. A set of SNPs with 95% probability of
containing the causal SNP was deﬁned as the smallest number of SNPs for which
the summed posterior probabilities exceed 0.95.
RNA expression quantitative trait analysis of rs13390936. Using RNA
expression and genome-wide genotyping data from published14–16 and unpub-
lished eQTL studies of naïve and stimulated primary immune cell subsets in
healthy European adults, we correlated rs13390936 genotype with STAT4 RNA
expression. CD19+ B cells, CD14+ monocytes and CD56+CD3− NK cells were
separated from peripheral blood mononuclear cells by magnetic activating cell
sorting (Miltenyi). CD16+ neutrophils were isolated from granulocytes with CD16+
microbeads. Gene expression was quantiﬁed in total RNA from naïve cells, and
monocytes stimulated with lipopolysaccharide (for 2 or 24 h) or IFNγ (for 24 h),
with the Illumina HumanHT-12 v4 BeadChip gene expression array platform.
Genome-wide genotyping was performed with the Illumina HumanOmniExpress-
12v1.0 Beadchip and imputation undertaken using 1000G phase1 as the reference
panel.
Following QC of gene expression and genotyping data as previously
described14–16, rs13390936 genotype was correlated with STAT4 RNA expression
in each cell type: B cells (n = 279), NK cells (n = 245), neutrophils (n = 101), naïve
monocytes (n = 414) and stimulated monocytes (LPS 2 h, n = 261; LPS 24 h, n =
322; IFNγ 24 h, n = 367). Random-spline normalized and variance-stabilization
transformed STAT4 expression was correlated with genotype under by linear
regression and analysis of variance (ANOVA), including the ﬁrst 20 principal
components of gene expression data in each cell type/condition to account for
confounding variation. P values are calculated with F-tests (1 d.f.). Statistical
analysis was performed in R.
LD at STAT4 in study populations. LD plots of the STAT4 region in the Kenyan
GWAS discovery samples (n = 2857) and the European samples used in the RNA
eQTL analyses (n = 421) were constructed in Haploview v4.244. To quantify dif-
ferential LD between the Kenyan and European samples we used varLD45, quan-
tifying LD variation between the two populations in 50-SNP windows. Raw varLD
scores across all of chromosome 2 were standardized, and regions with standar-
dized varLD scores >95th centile (standardized varLD score >1.86) considered to
have evidence of differential LD between the two populations.
Protein phenotypes for rs13390936 in immune cell subsets. In archived
genomic DNA from 5911 individuals registered to the Oxford Biobank (NIHR
Oxford Biomedical Research Centre), rs13390936 was genotyped by the Oxford
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Biobank laboratory using a TaqMan assay (Applied Biosystems). Fifty-four
volunteers (32 females; median age 44 years, range 30–51 years) were recruited to
the study according to rs13390936 genotype (36 with the NTS-protective AA
genotype, 18 with the NTS-susceptible TT genotype). The study was approved by
the Oxfordshire Research Ethics Committee (COREC reference 06/Q1605/55), and
written informed consent was obtained from each volunteer.
Whole blood from each volunteer was collected into Lithium Heparin-
containing collection tubes (Vacutainer System, Becton Dickinson). One millilitre
of aliquots of whole blood from each volunteer were left unstimulated, or
stimulated with 10 ng/ml recombinant human IL-12 (catalogue #219-IL, R&D
Systems) or 106 cfu/ml NTS (Malawian clinical S. Typhimurium isolate D23580)
grown to mid-log phase, within 2 h of collection. In addition, 1 ml whole blood
aliquots were stimulated with phorbol 12-myristate 13-acetate (100 ng/ml)/
ionomycin (1 μg/ml, Sigma) to act as a positive control. Following stimulation,
samples were incubated at 37 °C. Following ex vivo stimulation of each sample,
intracellular IFNγ staining was performed. Brefeldin A (Becton Dickinson) was
added at 2 h post-stimulation to a ﬁnal concentration of 2 μg/ml. At 6 h post-
stimulation, samples were surface immunostained (20 min, 4 °C) following
erythrocyte lysis (Versalyse, Beckman Coulter) with allophycocyanin-conjugated
anti-CD3 (clone UCHT1, BD Biosciences), ﬂuorescein isothiocyanate-conjugated
anti-CD4 (clone RPA-T4, BD Biosciences) and phycoerythrin (PE)-conjugated
anti-CD56 (clone CMSSB, eBioscience) monoclonals. Samples were ﬁxed with
Fixation Medium A (Invitrogen), before permeabilization with Permeabilization
Medium B (Invitrogen) and intracellular staining with PE-Cy7-conjugated anti-
IFNγ monoclonal (clone B27, BD Biosciences) for 20 min at 4 °C.
Immunostained samples were acquired with a BD FACSCanto II and BD
FACSDiVa (BD Biosciences), and the data were analysed using FlowJo v10
(TreeStar). To minimize variation across batches, all antibodies were obtained prior
to volunteer recruitment and belonged to the same manufacturing lot number.
Prior to analysis, CS&T beads of the same lot were used to calibrate the ﬂow
cytometer, to ensure equivalent photomultiplier tube voltages between
experiments. Proportions of IFNγ+ NK cells were logit transformed prior to
analysis, and genotype–phenotype associations tested with linear regression and
ANOVA, adjusted for age and sex. P values are calculated with F-tests (1 d.f.).
Transformation did not normalize IFNγ+ CD4+ T cell proportions, and
genotype–phenotype associations were tested with nonparametric Wilcoxon's
rank-sum tests. There was no evidence of signiﬁcant batch effect (P< 0.05) on
IFNγ+ cell proportion for either NK cells (linear regression model, adjusted for
rs13390936 genotype and stimulation conditions) or CD4+ T cells (Kruskal–Wallis
test). There was no evidence of signiﬁcant inter-genotype inequality of variances
(Bartlett test; P< 0.05) of IFNγ+ NK cell proportions. Statistical analysis was
performed in R.
Protein phenotypes of rs13390936 in acute NTS bacteraemia. We collected
serum samples from a subset of the Malawian replication cases (n = 106). Methods
used for bacterial culture and NTS identiﬁcation and serotyping are as described
above. Following identiﬁcation of NTS in blood culture, the parent or guardian of
the child was approached for recruitment to the study. Having obtained written
informed consent, a venous blood sample was taken from the child during their
acute admission with NTS bacteraemia (median 1 day following collection of the
NTS-positive blood culture, range 0–5 days). Plasmodium falciparum parasitaemia
was tested with thick and thin Giemsa-stained blood ﬁlms. HIV status was
determined using Determine (Abbot Laboratories) and UniGold (Trinity Biotech)
rapid tests, and HIV infection was conﬁrmed in children <18 months by PCR.
Children with weight-for-age Z-scores >3 standard deviations below WHO median
values were classiﬁed as being malnourished. rs13390936 genotypes were assayed as
for the Malawian GWAS replication samples (above). Ethical approval for the
study was granted by the College of Medicine Research and Ethics Committee,
College of Medicine, University of Malawi.
Sera were separated from clotted whole blood within 2 h of venesection, and
stored at −80 °C prior to analysis. Serum IFNγ concentrations were assayed using a
Bio-Plex Pro 27-plex human cytokine ﬂuorescent bead-based assay (Bio-Rad
Laboratories) according to the manufacturer’s instructions on a Luminex-100
instrument (Bio-Rad Laboratories) using Bio-Plex Manager 4.1.1 software (Bio-
Rad). Assays were performed in three batches with rs13390936 genotypes
randomized across batches. IFNγ measurements below the detection limit of the
assay were assigned values of the half of the lower detection limit, and were
included in the analysis. Correlation of rs13390936 genotype with serum IFNγ
concentration during acute NTS bacteraemia was performed by linear regression
and ANOVA, adjusting for age, sex and NTS-associated co-morbidities (HIV,
malnutrition and malaria). Serum IFNγ concentrations were cube-root
transformed prior to analysis. P values are calculated with F-tests (1 d.f.). There was
no evidence of signiﬁcant inter-genotype inequality of variances (Bartlett test; P<
0.05) of IFNγ concentration. Statistical analysis was performed in R.
Model comparisons of rs13390936 in children with bacteraemia. We com-
pared models of association at rs13390936 across the six most frequently isolated
bacterial pathogens among cases of bacteraemia in the Kenyan discovery samples
in the all-cause bacteraemia GWAS10. Two thousand six hundred and ﬁfty-one
control samples and 1222 cases (Streptococcus pneumoniae, 427 cases; NTS, 177
cases; Staphylococcus aureus, 172 cases; Escherichia coli, 157 cases; β-haemolytic
Streptococci, 156 cases; Haemophilus inﬂuenzae type b, 133 cases) were included in
the analysis. Effect size estimates and 95% CIs were calculated by multinomial
logistic regression under a recessive model, using control status and each of the
bacterial pathogen subgroups as strata, and the ﬁrst 4 principal components as
covariates (Fig. 3a). We considered four models of effect across the bacterial
pathogens, deﬁned by the prior distributions on the effect size:
NULL : effect size ¼ 0; i:e: no associationwith any pathogen
SAME: effect size  N 0; 1ð Þ and fixed between pathogens ρ ¼ 1ð Þ
REL: effect size  N 0; 1ð Þ and correlated ρ ¼ 0:96ð Þ;
but not fixed; between pathogens
NTS : effect size  N 0; 1ð Þ for NTS and is zero for all other pathogens
For each model we calculated approximate Bayes factors43 and posterior prob-
abilities (Fig. 3b), assuming each model to be equally likely a priori. Statistical
analysis was performed in R.
Using the same approach, we compared models of association at rs13390936 in
subgroups of children with NTS bacteraemia in the Kenyan discovery samples. We
compared models of association in children with NTS bacteraemia secondary to S.
Enteritidis and S. Typhimurium (82 S. Enteritidis cases, 65 S. Typhimurium cases,
2651 controls), and in children with NTS bacteraemia with and without acquired
risk factors for NTS disease (57 NTS cases with malaria, 129 NTS cases without
malaria, 2651 controls; 65 NTS cases with malnutrition, 101 NTS cases without
malnutrition, 2651 controls).
Model comparisons of rs13390936 in autoimmune diseases. To compare
evidence for association at rs13390936 across a range of autoimmune diseases, we
downloaded from ImmunoBase21 summary statistics of disease associations at
rs16833239 (in perfect LD with rs13390936 in CEU 1000 Genomes Pilot 1
population; r2 = 1, D′ = 1) for nine association studies of eight autoimmune diseases
(coeliac disease, rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis,
narcolepsy, juvenile idiopathic arthritis, psoriasis and type 1 diabetes—one
case–control study and one meta-analysis of case–control and family-based stu-
dies) conducted using the ImmunoChip39 in individuals of European ancestry18–
21,46–49. Standard errors were estimated from reported odds ratios and P values
calculated under an additive model (Fig. 3c).
Consortia. Sample collection, DNA extraction and phenotyping of the Kenyan
children presented in this study were generated by the Kenyan Bacteraemia Study
Group. Genome-wide genotyping data of the Kenyan samples was generated by the
Wellcome Trust Case Control Consortium 2. Memberships of both consortia are
provided in the Supplementary Information.
Data availability. Genotype and phenotype data for Kenyan discovery and
replication samples are available via the European Genotype Archive, with the
accession code EGAS00001001756. Genotype and phenotype data for Malawian
replication samples are available on request from the corresponding authors.
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